Ganz, Joranson receive ACS Distinguished Service Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

ATLANTA—The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

Dr. Ganz, a professor in the UCLA Schools of Medicine and Public Health and a founding member of the National Coalition for Cancer Survivorship, was recognized for her major contributions and commitment in the field of cancer research. For 2 decades, Dr. Ganz has conducted ground-breaking research that has changed the face of cancer survivorship. Last year, she was selected to head up the UCLA-Livestrong Survivorship Center of Excellence, which addresses the needs of the ever-increasing number of cancer survivors in the United States.

Mr. Joranson was honored for his contributions to the study and modernization of narcotics control policies to remove barriers to pain patients' access to opioid analgesics, ACS said. As director of the World Health Organization Collaborating Center for Policy and Communications in Cancer Care, he has led efforts to achieve more balanced national drug control policies and improve patient access to pain drugs in developing countries.

Recent Videos
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Related Content